

08-07-00

08/04/00  
09/632735  
JCS63 U.S. PTO

Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

Attorney Docket No. RG0107US (#90236)

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): **Maria Isabel Baeza-Ramírez, José Leopoldo Aguilar-Faisal,  
Carlos Wong-Ramírez, Miguel Angel Ibáñez-Hernández and  
Monica Lara-Uc**

For: **METHODS FOR DIAGNOSTIC AND/OR TREATMENT OF  
ANTIPHOSPHOLIPIDS ANTIBODIES-RELATED DISEASES, AND DEVICES**

**1. Type of Application**

This new application is for a(n) (check one applicable item below):

- (X) Original  
( ) Design  
( ) Plant  
( ) Divisional  
( ) Continuation  
( ) Continuation-in-part (CIP)

**\*\*NOTE:** If one of the following 3 items apply, then complete and attach added pages for new application transmittal where benefit of a prior U.S. application claimed.

**CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date noted below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EK980729890US addressed: Box Patent Application, Commissioner for Patents, Washington, D.C. 20231.

Christine A. Kotran  
(Type name of persons mailing paper)

Date August 4, 2000

6/2000/ck

Christine A. Kotran

## 2. Benefit of Prior U.S. Application(s) (35 USC 120)

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., then check the following item and complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OR PRIOR U.S. APPLICATION(S) CLAIMED.

NOTE: **Each** paper or fee referred to as enclosed herein has the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 CFR 1.10(b)

- ☐ The new application being transmitted claims the benefit of prior U.S. application(s) and enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

## 3. Papers Enclosed Which are Required For Filing Date Under 37 CFR 1.53(b) (Regular) or 37 CFR 1.153 (Design) Application

- ☒ 56 Pages of specification (**Spanish language text**)  
☒ 4 Pages of claims (31 claims)  
☒ 1 Pages of Abstract  
☒ 17 Sheets of drawing  
    ☐ formal  
    ☒ informal

## 4. Additional papers enclosed

- ☐ Preliminary Amendment  
☐ Information Disclosure Statement  
☐ Form PTO-1449  
☐ Citations  
☐ Declaration of Biological Deposit  
☐ Special Comments  
☐ Other

## 5. Declaration or oath

- ☐ Enclosed  
    executed by (check **all** applicable boxes)  
    ☐ inventor(s).  
    ☐ legal representative of inventor(s). 37 CFR 1.42 or 1.43

- ☐ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.
- ☐ this is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. See item 12 below for fee.
- ☒ Not Enclosed.
- ☐ Application is made by a person authorized under 37 CFR 1.41(c) on behalf of all the above named inventor(s). The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently.
- ☐ Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).

## 6. Inventorship Statement

**WARNING:** If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.

The inventorship for all the claims in this application are:

- ☒ The same
- or**
- ☐ Are not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,
  - ☐ is submitted
  - ☐ will be submitted.

## 7. Language

NOTE: An application including a signed oath or declaration may be filed in a language other than English. A verified English translation of the non-English language application and the processing fee of \$130.00 required by 37 CFR 1.17(k) is required to be filed with the application or within such time as may be set by the Office. 37 CFR 1.52(d).

NOTE: A non-English oath or declaration in the form provided or approved by the PTO need not be translated. 37 CFR 1.69(b).

- ☐ English
- ☒ Non-English (**Spanish language text**)
- ☐ the attached translation is a verified translation. 37 CFR 1.52(d).

**8. Assignment**

- (X) An assignment of the invention to: Escuela Nacional de Ciencias Biológicas del  
Instituto Politécnico Nacional  
( ) is attached (with separate transmittal)  
(X) will follow

**9. Certified Copy**

Certified copy(ies) of application(s)

(country)	(appl. no.)	(filed)
(country)	(appl. no.)	(filed)
(country)	(appl. no.)	(filed)

from which priority is claimed

- ( ) is (are) attached  
( ) will follow

NOTE: The foreign application forming the basis for the claim for priority **must** be referred to in the **oath** or **declaration**. 37 CFR 1.55(a) and 1.63.

NOTE: This item is for any foreign priority for which the application being filed directly relates. if any parent U.S. application or International Application form which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application then complete item 17 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OR PRIOR U.S. APPLICATION(S) CLAIMED.

## 10. Fee Calculation

### A. (X) Regular application

CLAIMS AS FILED			
Number Filed	Number Extra	Rate	Basic Fee \$690.00
Total Claims	-20 =	---	X \$18.00 =
Independent Claims	- 3 =	---	X \$78.00 =

Multiple dependent claim(s), if any X \$260.00 =

- ☐ Amendment canceling extra claims enclosed
- ☐ Amendment deleting multiple dependencies enclosed
- ☒ Fee for extra claims is not being paid at this time

NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims canceled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 CFR 1.16(d).

Filing Fee Calculation \$690.00

### B. () Design application

(\$310.00 - 37 CFR 1.16(f))

Filing Fee Calculation \$

## 11. Small Entity Statement(s)

- ☐ Verified Statement(s) that this is a filing by a small entity under 37 CFR 1.9 and 1.27 is(are) attached.

Filing Fee Calculation (50% of A or B above) \$

NOTE: Any excess of the full fee paid will be refunded if a verified statement and a refund request are filed within 2 months of the date of timely payment of a full fee. 37 CFR 1.28(a).

## 12. Fee Payment Being Made At This Time

- ☐ Not Enclosed
- ☐ No filing fee is to be paid at this time. (This and the surcharge required by 37 CFR 1.16(e) can be paid subsequently.)
- ☒ Enclosed
- |  |                        |
|--|------------------------|
| <input checked="" type="checkbox"/> basic filing fee   | \$690.00               |
| <input type="checkbox"/> recording assignment<br>(\$40.00; 37 CFR 1.21(h)(1))  | \$                     |
| <input type="checkbox"/> petition fee for filing by<br>other than all the inventors<br>or person on behalf of the<br>inventor where inventor refused<br>to sign or cannot be reached.<br>(\$130.00; 37 CFR 1.47 & 1.17(h)) | \$                     |
| <input type="checkbox"/> for processing an application<br>with a specification in a<br>non-English language. (\$130.00<br>37 CFR 1.52(d) and 1.17(k))  | \$                     |
| <input type="checkbox"/> processing and retention fee<br>(\$130.00; 37 CFR 1.53(d) and<br>1.21(l))   | \$                     |
| <b>Total fees enclosed</b>   | <b><u>\$690.00</u></b> |

## 13. Method of Payment of Fees

- ☒ Check in the amount of **\$690.00**
- ☐ Charge Account No. 08-2441 in the amount of \$
- A duplicate of this transmittal is attached.

NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 CFR 1.22(b).

## 14. Authorization to Charge Additional Fees

**WARNING:** If no fees are to be paid on filing the following items should **not** be completed.

**WARNING:** Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.

(X) The Commissioner is hereby authorized to charge the following additional fees required by this paper and during the entire pendency of this application to Deposit Account No. 08-2441.

(X) 37 CFR 1.16 (filing fees)

(X) 37 CFR 1.16 (presentation of extra claims)

(X) 37 CFR 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)

(X) 37 CFR 1.17 (application processing fees)


( ) 37 CFR 1.18 (issue fee at or before mailing Notice of Allowance, pursuant to 37 CFR 1.311(b).

### 15. Instruction As To Overpayment

( ) Credit Account No. 08-2441. This transmittal is submitted in duplicate.

(X) **Refund** directly to the undersigned, **specifically identifying our Docket No. RG0107US.**

Respectfully submitted,

By:   
D. Peter Hochberg  
Reg. No. 24,603

DPH/ck  
Enc.

D. Peter Hochberg Co., L.P.A.  
1940 East 6th Street - 6<sup>th</sup> Floor  
Cleveland, Ohio 44114-2294  
(216) 771-3800

#### ( ) Incorporation by reference of added pages

Check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attached the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

( ) Plus Added Pages For New Application Transmittal Wherein

Benefit Of Prior U.S. Application(s) Claimed

Number of pages added \_\_\_\_\_

( ) Plus Added Pages For Papers Referred To In Item 4 Above

Number of pages added \_\_\_\_\_

#### (X) Statement Where No Further Pages Added

If no further pages from a part of this Transmittal then end this Transmittal with his page and check the following item

(X) This transmittal ends with this page.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Maria Isabel Baeza-Ramirez, José Leopoldo Aguilar-Faisal, Carlos Wong-Ramirez, Miguel Angel Ibañez-Hernandez, Mónica Lara-Uc

Serial No. : 09/632,735 Group Art Unit : 1614

Filing : August 4, 2000 Examiner :

Title : METHODS FOR DIAGNOSTIC AND/OR TREATMENT OF ANTIPHOSPHOLIPIDS ANTIBODIES-RELATED DISEASES, AND DEVICES

Attorney File : RG0107US (#90236)

Box Missing Parts FEE  
Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to substantive examination of the above-identified application, please amend the application, without prejudice, as follows:

In the specification:

Page 7, delete lines 17-21 and insert the following: -- This second hypothesis was proposed in the Master Thesis presented by Monica Lara on August 20, 1999 ("Detection of anti-lipidic particles antibodies in patients with the antiphospholipid syndrome," Master Thesis, Escuela Nacional de Ciencias Biológicas [National School of Biological Sciences], Instituto Politécnico Nacional [National Polytechnic Institute], Mexico). --

Page 10, delete lines 16-18 and insert the following: -- Figure 11 is a photograph of a seven (7) month old BALB/c female mouse immunized with PC:PA (2:1 mole ratio) liposomes bearing



lipidic particles induced by chlorpromazine, where alopecia and lesions on the face in the form of butterfly wings are observed. --

Page 11, line 12, replace "Nevertheless" with -- Despite -- .

In the claims:

Please delete claim 17.

1. (Amended) A diagnosis method for determining if an individual having clinical characteristics of the primary antiphospholipid syndrome or diseases associated [to] with the secondary antiphospholipid syndrome, and who does not yet present [yet] anti-cardiolipine antibodies, lupus anticoagulant, anti-DNA or antinuclear antibodies[;], does have a disease associated [to] with the presence of antiphospholipid antibodies[;], comprising the steps of:

detecting, in a direct or indirect fashion using a detection protocol, the presence [or absence] of lipidic particles in a serum sample from said individual[,]; and

observing whether lipidic particles are detected or not[; where], the presence of said lipidic particles indicat[es]ing the development of a disease associated to the presence of antiphospholipid antibodies in said individual.

Claim 2, line 3, replace "a sample from the individual" with -- the serum sample -- .

3. (Amended) A method in accordance with claim 1, wherein the serum sample from said individual is selected [between] from serum and plasma of said individual, and the antigen containing lipidic particles is selected [between] from neoplastic cells and liposomes.

Claim 4, line 2, replace "at least" with -- at least one of -- , replace "or" with -- and -- , line 4, replace "individual's" with -- serum -- .

Claim 5, line 3, replace "at least" with -- at least one of -- , replace "or" with -- and -- .

Claim 6, line 4, delete "at least", line 5, delete "at least", line 6, delete "at least", line 8, delete "at least", delete "ill", line 9, delete "individual's".

Claim 7, line 3, replace "wherein enzymatic" with -- wherein the enzymatic -- .

Claim 8, line 2, replace "between" with -- from -- .

Claim 9, lines 1-2, replace "at least a sample" with -- a reference sample -- .

Claim 11, line 5, delete "at least", delete "ill", line 6, delete "individual's".

Claim 13, line 2, replace "between" with -- from -- .

Claim 14, line 1, delete "at least", line 3, replace "at least a sample" with -- a reference sample -- .

Claim 16, line 4, delete "at least", line 6, delete "at least", delete "ill", line 7, delete "individual's", line 8, replace "fluorescent" with -- at least one of fluorescent and enzymatic -- .

Claim 18, line 1, replace "claims 16 or 17" with -- claim 16 -- .

Claim 22, line 2, replace "to" with -- with -- , line 5, replace ";" with -- , -- .

Claim 24, line 2, replace "to" with -- with -- , line 5, replace ";" with -- , -- .


Claim 25, line 1, after "wherein", insert -- the-- , line 3, replace ";" with -- , -- .

Claim 26, line 2, replace "characterized in that it includes the detection of" with -- comprising detecting -- .

Claim 27, line 3, delete "at least", line 5, delete "at least", line 7, replace "fluorescent or", with -- at least one of fluorescent and -- .


### REMARKS

The foregoing amendments to the application are made to place it in conformance with U.S.



patent practice, to more precisely disclose the invention, and to delete multiple dependencies in the claims, thus reducing the government filing fee. No new matter has been added to the application by this amendment. Accordingly, prosecution on the merits hereof is respectfully requested.

Respectfully submitted,

By:   
D. Peter Hochberg  
Reg. No. 24,603

DPH/KRV

D. Peter Hochberg Co., L.P.A.  
The Baker Building - 6th Floor  
1940 East 6th Street  
Cleveland, Ohio 44114  
(216) 771-3800

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

I hereby certify that this paper, and any documents or thing identified as being attached or enclosed herewith, is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed: Commissioner for Patents, Washington, DC 20231, on the date noted below.

Jan. 25, 2001  
Date

  
Signature

KATHERINE R. VIEIRA  
Name of Person Mailing Paper

Practitioner's Docket No. RG0107US (#90236)

## PATENT

XXX Applicant Maria Isabel Baeza-Ramirez et al.

☐ **Patentes** \_\_\_\_\_

XXX Application No. 09/632,735

☐ Patent No. \_\_\_\_\_

XXIX Filed on 08/04/2000

☐ Issued on \_\_\_\_\_

**Title:** METHODS FOR DIAGNOSTIC AND/OR TREATMENT OF ANTIPHOSPHOLIPIDS  
ANTIBODIES-RELATED DISEASES AND DEVICES

**STATEMENT CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(f) and 1.27(d))—NONPROFIT ORGANIZATION**

I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below: ESCUELA NACIONAL DE CIENCIAS BIOLOGICAS, D

Identified below: ESCUELA NACIONAL DE CIENCIAS BIOLOGICAS, DEL  
Name of Nonprofit Organization INSTITUTO POLITECNICO NACIONAL.

**Address of Nonprofit Organization** Prolongación de Carpio y Plan de Ayala, Colonia Santo  
Tomas, C.P. 11340, D.F., México

**TYPE OF NONPROFIT ORGANIZATION**

- ☒ University or Other Institution of Higher Education
- ☐ Tax Exempt Under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3))
- ☐ Nonprofit Scientific or Educational Under Statute of State of the United States of America
- (Name of State \_\_\_\_\_)
- (Citation of Statute \_\_\_\_\_)
- ☐ Would Qualify as Tax Exempt Under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3)), If Located in the United States of America
- ☐ Would Qualify as Nonprofit Scientific or Educational Under Statute of State of the United States of America if Located in the United States of America
- (Name of State \_\_\_\_\_)
- (Citation of Statute \_\_\_\_\_)

I hereby state that the nonprofit organization identified above qualifies as a nonprofit organization, as defined in 37 CFR 1.9(e), for purposes of paying reduced fees to the United States Patent and Trademark Office under Sections 41(a) and (b) of Title 35, United States Code, with regard to the invention described in

- ☐ the specification filed herewith, with title as listed above.  
X ☒ the application identified above.  
☐ the patent identified above.

I hereby state that rights under contract or law have been conveyed to, and remain with, the nonprofit organization, with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below" and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. 1.9(c), if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e)

*\*NOTE: Separate statements are required from each named person, concern or organization having rights to the invention as to their status as small entities. (37 CFR 1.27).*

Each such person, concern or organization having any rights in the invention is listed below:

☒ No such person, concern, or organization exists.

☐ Each such person, concern or organization is listed below.

Name \_\_\_\_\_

Address \_\_\_\_\_

☐ INDIVIDUAL      ☐ SMALL BUSINESS CONCERN      ☐ NONPROFIT ORGANIZATION

Name \_\_\_\_\_

Address \_\_\_\_\_

☐ INDIVIDUAL      ☐ SMALL BUSINESS CONCERN      ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

*(check the following item, if desired)*

*NOTE: The following verification statement need not be made in accordance with the rules published on Oct. 10, 1997, 62 Fed. Reg. 52,131, effective Dec. 1, 1997.*

*NOTE: "The presentation to the Office (whether by signing, filing, submitting, or later advocating) of any paper by a party, whether a practitioner or non-practitioner, constitutes a certification under § 10.18(b) of this chapter. Violations of § 10.18(b)(2) of this chapter by a party, whether a practitioner or non-practitioner, may result in the imposition of sanctions under § 10.18(c) of this chapter. Any practitioner violating § 10.18(b) may also be subject to disciplinary action. See §§ 10.18(d) and 10.23(c)(15)." 37 C.F.R. § 1.4(d)(2).*

☒ I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing Dr. Francisco Javier OSORNIO - CORRES  
Title in Organization Abogado General y Representante Legal del IPN.  
Address of Person Signing Avenida Luis Enrique Erro sin número,  
Unidad Profesional "Adolfo López Mateos", colonia Zacatenco, Delegación  
Gustavo A. Madero, 07738 Ciudad de México, Distrito Federal, México.

SIGNATURE




Date Agosto 17 del 2000

Name of Person Signing M. en C. María Dolores GUTIERREZ - PASTRANA  
Title in Organization Directora  
Address of Person Signing Prolongación de Carpio y Plan de Ayala,  
Colonia Santo Tomás, C.P. 11340, D.F., México.

SIGNATURE



Date 14 de agosto del 2000



**Figura 1**





Figura 2.





**Figura 3**

000000 55 66 3300




Figura 4 A

004053 00000000






Figura 4 B



**Figura 5**



**Figura 6**

004080 5525550




Figura 7





Figura 8

001060-5526360



**Figura 9**






Figura 10



**Figura 11**

001050.927690







Figura 12




Fosforilcolina




Fosforilserina



Fosforiletanolamina



Glicerolfosforilcolina



Glicerolfosforilserina

Figura 13

004030, 5/2/2000




Figura 14




Figura 15




Figura 16

#3

Attorney Docket No. RG0107US (# 90236)

## COMBINED DECLARATION AND POWER OF ATTORNEY

(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL,  
DIVISIONAL, CONTINUATION OR CIP)

As a below named inventor, I hereby declare that:

### TYPE OF DECLARATION

This declaration is of the following type: (check one applicable item below)

- ☒ original  
☐ design

NOTE: If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application do not check any of next two items and check appropriate one of last three items.

- ☐ national stage of PCT  
☐ supplemental

NOTE: If one of the following 3 items apply then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR CIP.

- ☐ divisional  
☐ continuation  
☐ continuation-in-part (CIP)

### INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

### TITLE OF INVENTION

METHODS FOR DIAGNOSTIC AND/OR TREATMENT OF ANTIPHOSPHOLIPIDS  
ANTIBODIES-RELATED DISEASES, AND DEVICES.

### SPECIFICATION IDENTIFICATION

the specification of which: (complete (a), (b), or (c))

- (a) (XX) is attached hereto. (and (b) below)  
(b) (XX) was filed on 8/4/2000 as ( ) Serial No. 09/632,735 or  
( ) Express Mail No. , as Serial No. not yet known  
and was amended on (if applicable).



- (c) ( ) was described and claimed in PCT International Application No. \_\_\_\_\_ filed on \_\_\_\_\_ and as amended under PCT Article 19 on \_\_\_\_\_ (if any).

### ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations. Sec. 1.56(a).

- ( ) In compliance with this duty there is attached an information disclosure statement. 37 CFR 1.97.

### PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, Sec. 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) (xx) no such applications have been filed.  
(e) ( ) such applications have been filed as follows

NOTE: Where item (c) is entered above and the International Application which designated the U.S. claimed priority check item (e), enter the details below and make the priority claim.

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

COUNTRY	APPLICATION NO.	DATE OF FILING (month, day, year)	PRIORITY CLAIMED UNDER 37 USC 119
_____	_____	_____	( ) YES NO ( )
_____	_____	_____	( ) YES NO ( )
_____	_____	_____	( ) YES NO ( )

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

**POWER OF ATTORNEY**

As a named inventor, I hereby appoint D. Peter Hochberg, Reg. No. 24,603, Michael J. Corrigan, Reg. No. 42,440, and William H. Holt, Reg. No. 20,766, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

**SEND CORRESPONDENCE TO:**

D. Peter Hochberg Co., L.P.A.  
1940 East 6th Street - 6<sup>TH</sup> Floor  
Cleveland, Ohio 44114-2294

**DIRECT TELEPHONE CALLS TO:**  
(Name and telephone number)

D. Peter Hochberg  
(216) 771-3800

**DECLARATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**SIGNATURE(S)**

Full name of sole or first inventor: María Isabel BAEZA-RAMIREZ

Inventor's signature

*Baeza Ramirez Ma. I.*

Agosto 14, 2000

México

Date

Country of Citizenship


Prolongación de Carpio y Plan de Ayala, Coloina Santo Tomas, C.P11340.D.F.

Residence

AP-256

Post Office Address

Full name of second joint inventor, if any: José Leopoldo AGUILAR-FAISAL

  
Inventor's signature

Agosto 14, 2000

México

Date

Country of Citizenship

Prolongación de Carpio y Plan de Ayala, Colonia santo Tomas, 11340, D. F.

Residence  
AP-256

Post

CHECK PROPER BOX(ES) IF ANY OF THE FOLLOWING ADDED PAGE(S)  
FORM A PART OF THIS DECLARATION

- 001000-5422590
- ( x ) Signature for third and subsequent joint inventors. Number of pages added 1.
  - ( ) Signature by administrator(trix), executor(trix) or legal representative of deceased or incapacitated inventor. Number of pages added \_\_\_\_\_.
  - ( ) Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added \_\_\_\_\_.

\*\*\*

- ( ) Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (CIP) application.
- ( ) Number of pages added \_\_\_\_\_.

\*\*\*

If no further pages form a part of this Declaration then end this Declaration with this page and check the following item.

( ) This declaration ends with this page.

Full Name of **third joint inventor**:

Carlos Wong Ramirez

Inventor's signature



August 14 - 2000

Date

México  
Country of Citizenship

Prolongación de Carpio y Plan de Ayala, Colonia Santo Tomas, 11340, D.F.  
Residence

AP-256

Post

Full Name of **fourth joint inventor**:

Miguel Angel Ibáñez Hernández

Inventor's signature

August 14 - 2000

Date

México  
Country of Citizenship

Prolongación de Carpio y Plan de Ayala, Colonia Santo Tomas, 11340, D. F.  
Residence

AP-256

Post

Full Name of **fifth joint inventor**: Mónica Lara Uc

Inventor's signature

August 14 - 2000


Date

México  
Country of Citizenship

Prolongación de Carpio y Plan de Ayala, Colonia Santo Tomas, C.P 11340, D. F.  
Residence

AP-256

Post



#3

Attorney Docket No. RG0107US (#90236)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Maria Isabel Baeza-Ramirez, José Leopoldo Aguilar-Faisal, Carlos Wong-Ramirez, Miguel Angel Ibañez-Hernandez, Mónica Lara-Uc

Serial No. : 09/632,735 Group Art Unit : 1614

Filing : August 4, 2000 Examiner :

Title : METHODS FOR DIAGNOSTIC AND/OR TREATMENT OF  
ANTIPHOSPHOLIPIDS ANTIBODIES-RELATED DISEASES, AND  
DEVICES


Box MISSING PARTS - FEE  
Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT**

Sir:

I, D. Peter Hochberg, an attorney registered in the United States Patent and Trademark Office, declare that the application filed in the Patent and Trademark Office on August 4, 2000 is the application which the inventors executed by signing the attached Combined Declaration and Power of Attorney.


Respectfully submitted,



By:   
D. Peter Hochberg  
Reg. No. 24,603

DPH/KRV / Attachments  
D. PETER HOCHBERG CO., L.P.A.  
1940 East 6<sup>th</sup> Street, 6<sup>th</sup> Floor  
Cleveland, Ohio 44114  
(216) 771-3800

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

I hereby certify that this paper, and any documents or thing identified as being attached or enclosed herewith, is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed: Box Missing Parts - Fee, Commissioner for Patents, Washington, DC 20231, on the date noted below.

  
Date

  
Signature  
  
Name of Person Mailing Paper